RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (July 2016)

35 slides from RespireRx Pharmaceuticals's investor presentation, Jul 13, 2016

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements GQ RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "ex

  3. Slide 3: Breath

    Breath A "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." bene Abbot George Burke

  4. Slide 4: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases A) RespireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent

  5. Slide 5: Company Focus

    Company Focus Gd RespireRx o Sleep Apneas * Dronabinol for Obstructive Sleep Apnea (OSA) « Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation " Semi-acute use — post-surgical pain management with opioids " Chronic

  6. Slide 6: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline Do RespireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea | aD Central Sleep Apnea —_—_——sy? CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CXx717 with Opioids for Reduced Respirator

  7. Slide 7: Sleep Apnea

    Sleep Apnea BR RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas =

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) RespireRx o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stroke, hypertension, heart

  9. Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    RespireRx Pharmaceuticals Inc CPAP Efficacy is Severely Limited by Patient Compliance WN o Standard of Care o Works as an air splint to keep upper airway open during sleep o 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine o Over 50% of patients stop using CPAP in th

  10. Slide 10: Dronabinol: Breakthrough Treatment for OSA

    Dronabinol: Breakthrough Treatment for OSA A) RespireRx o Mechanism of Action " Dronabinol is (delta 9) THC, a cannabinoid agonist o Background * Schedule III drug available by prescription, with a low risk of addiction « Approved for the treatment of anorexia in AIDS patients and nausea and vomitin

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of Dronabinol in OSA A) RespireRx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days » 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at bas

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Dronabinol Proven to Reduce Apnea in OSA Subjects RespireRx 40% -20% -30% -40% oO o —— c 30% Q < 20% Q P=0.17 o a woe Dronabinol n 0% = Placebo “10% c A P<0.01 = o a nod o ir 12

  13. Slide 13: Apnea Suppression as a Function of Dose and Time

    Apnea Suppression as a Function of Dose and Time RespireRx Pharmaceuticals Inc AAHI versus Baseline & 8 8 ist Half m 2nd Half “16 A] “18 n=17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13

  14. Slide 14: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Ongoing Dronabinol Phase 2B Clinical Trial in OSA A) RespireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Potentially pivotal for an NDA submission o Doses: Placebo, 2.5 mg, 10 mg qd o All 120 subjects dosed (40/group, 6 weeks dosing) o Data analysis underway; read

  15. Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market Gd RespireRx o Licensed issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical marijuana a

  16. Slide 16: The Dronabinol Opportunity

    The Dronabinol Opportunity Gd RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Changes the nature of OSA treatment Ease of Use/Better Patient Compliance Broadly expands prescriber base from sleep specialists to include primary care physicians an

  17. Slide 17: Central Sleep Apnea

    Central Sleep Apnea GQ RespireRx Pharmaceuticals Inc o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA « 70% of chronic narcotic users = Up to 40% of heart failure patients « 5% of sleep apnea patients are idiopathic o No medicine or device is approved for th

  18. Slide 18: Severity of CSA is Correlated with Increased Mortality in Heart Failure Patients

    Severity of CSA is Correlated with Increased Mortality in Heart Failure Patients RespireRx Pharmaceuticals Inc mw 2 a ft? AHI less than 5 per hour b --@ AH] equal or greater than S per hour ea . Ba *, Reducing Central 7 : : 7 g Sleep Apnea May 2S | Reduce Mortality in 2 oo Heart Failure Patients — “

  19. Slide 19: AMPAKINES — A Novel Class of Medicines

    RespireRx Pharmaceuticals Inc AMPAKINES — A Novel Class of Medicines AMPA Receptors Mediate Synaptic Transmission in the Brain o Glutamate is the major y excitatory neurotransmitter in ae the CNS a o Fast excitatory transmission is So F sceegnayine mediated by AMPA-type \/ tarnato glutamate receptor

  20. Slide 20: AMPAKINES — Novel Treatments for Respiratory Depression

    AMPAKINES — Novel Treatments for Respiratory Depression G&)Resp pireRx Initial research conducted by Dr. J. Greer, U. Alberta Ren et al, Anesthesiology. 110:1364-1370, 2009 Pharmaceuticals Inc PreBotzinger PreBotzinger Complex Complex Neurons in this brainstem region control inspiratory breathing rh

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine

    CX1739: A Third Generation, Oral Ampakine in Phase 2 A) RespireRx Pharmaceuticals Inc o Targeted Indications " Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression " Combination formulation with an opioid for treatment of chronic pain o Stage of Development *

  22. Slide 22: CX1739: Completed Phase 2A in Sleep Apnea

    CX1739: Completed Phase 2A in Sleep Apnea Resp pireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of

  23. Slide 23: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas RespireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea : TT 0 iS y ey LN y ¢ ev 6 xs Ss e s % e ff ff ez ge g a s g 8 3 a a (Events/hr) 2aaNnNn 8 Apnea Index 3 Apnea Index {Events/hr) ° Rao h

  24. Slide 24: Drug-induced Respiratory Depression

    Drug-induced Respiratory Depression RespireRx Pharmaceuticals Inc RD is the most frequent lethal side effect of opioid use o Acute and Semi-Acute Use of opioids = ~25M patients/year at risk for Respiratory Depression (hospitalized, peri- and post-surgical opioid patients) ° Chronic Opioid Use = Use

  25. Slide 25: Ampakines Prevent Opioid-induced Respiratory Depression

    Ampakines Prevent Opioid-induced Respiratory Depression Pharmaceuticals Inc Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil Respiratory and analgesia end-point

  26. Slide 26: CX717 Prevents Opioid-induced Respiratory Depression in Humans

    CX717 Prevents Opioid-induced Respiratory Depression in Humans RespireRx Pharmaceuticals Inc 16 NS #e (Placebo 9X7 17 12 ** P'<0.01 NS - Not Significant Breaths/min co is Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. Baseline +Alfentanil +Naloxone Al

  27. Slide 27: CX717 Does Not Interfere With the Analgesic Properties of Opioids

    CX717 Does Delivery of a electrical stimulation to finger Not Interfere With the Analgesic Properties of Opioids Pharmaceuticals Inc Analgesia 2.0 (“Placebo i 2 15 @CX717 G) = | = EB) 210 NS = ins i= so a 05 0.0 Baseline +Alfentanil +Naloxone Data are expressed as the pain sensitivity, normalized to

  28. Slide 28: CX1739: Phase 2A in Opioid-Induced Respiratory Depression

    CX1739: Phase 2A in Opioid-Induced Respiratory Depression BN RespireRx Pharmaceuticals Inc Protocol Antagonism of Opioid-Induced Respiratory Depression by CX1739 with Preservation of Opioid Analgesia Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing Each subject

  29. Slide 29: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline Do RespireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea | aD Central Sleep Apnea —_—_——sy? CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CXx717 with Opioids for Reduced Repertory

  30. Slide 30: NIH-Supported Programs in Drug Abuse

    NIH-Supported Programs in Drug Abuse RespireRx o Non-Core Programs in Drug Abuse and Addiction Cocaine and Amphetamines Research and development program with NIDA NIDA contracts with specialist labs and pays for animal studies Company provides compounds and retains all rights 30

  31. Slide 31: Capital Structure & Market Metrics

    Capital Structure (thousands of shares) & Market Metrics RespireRx Pharmaceuticals Inc Total as of May 31, 2016 Common Stock 648,768 Common Stock Equivalents of Convertible Notes 9,153 Common Stock Equivalents of all Options and Warrants Granted 556,251 Total 1,214,172 May 31, 2016 Closing price per

  32. Slide 32: Management and Directors

    Management and Directors RespireRx Pharmaceuticals Inc James Manuso President, CEO & Vice Chairman Arnold Lippa CSO & Chairman Jeff Margolis VP, Secretary/Treasurer, Director Robert Weingarten CFO, Director Richard Purcell Senior VP, R& D Katie MacFarlane Director CCO Agile Therapeutics James Sapirs

  33. Slide 33: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases WN ° ° ° fe} Two proprietary, small molecule platforms Three Phase 2 or Phase 2-ready development programs Three pre-clinical programs Focus on blockbuster markets with unmet clinical needs More than 120 + patents and patent applications Multiple opportu

  34. Slide 34: Strategic Considerations, Post-Phase II Results

    Strategic Considerations, Post-Phase II Results GQ) RespireRx Pharmaceuticals Inc o Prepare RSPI for an up-listing to NASDAQ o Engage advisor to assist with capital raising o Directly manage all trials of medicines in development o Partner/License/Sell one or more medicines in development o Partner/

  35. Slide 35: Medicines for Respiratory Diseases

    Pharmaceuticals Inc Medicines for Respiratory Diseases

RespireRx Pharmaceuticals — Investor Presentation (July 2016) on 6ix